Literature DB >> 2491835

In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M, and A against Pseudomonas aeruginosa lipopolysaccharide.

G B Pier1, D Thomas, G Small, A Siadak, H Zweerink.   

Abstract

We evaluated the in vitro opsonophagocytic killing activity of monoclonal human immunoglobulin G (IgG), IgM, and IgA specific for Pseudomonas aeruginosa lipopolysaccharide and the in vivo protective capacity in neutropenic mice of both monoclonal and purified polyclonal IgG, IgM, and IgA. Monoclonal IgM was efficacious in mediating opsonophagocytic killing only in conjunction with complement, whereas monoclonal IgG opsonic killing was potentiated by complement, and monoclonal IgA opsonic killing was independent of complement. These findings are similar to those previously reported for purified polyclonal IgM, IgG, and IgA. The monoclonal and polyclonal immunoglobulins had comparable 50% protective doses in neutropenic mice (range, 0.28 to 0.46 microgram per mouse). The protective activity of IgM in neutropenic mice was abolished by cobra venom factor treatment, whereas IgG and IgA maintained efficacy in cobra venom factor-treated mice. These data indicate that all three major human serum immunoglobulin isotypes have opsonophagocytic and protective activities against P. aeruginosa, with a critical role for complement in the function of IgM.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2491835      PMCID: PMC313063          DOI: 10.1128/iai.57.1.174-179.1989

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  Structural analysis and immunogenicity of Pseudomonas aeruginosa immunotype 2 high molecular weight polysaccharide.

Authors:  G B Pier; S E Bennett
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

2.  C5 chemotactic fragments produced by an enzyme in lysosomal granules of neutrophils.

Authors:  P A Ward; J H Hill
Journal:  J Immunol       Date:  1970-03       Impact factor: 5.422

3.  Pulmonary clearance of Pseudomonas aeruginosa in neutropenic mice. Effects of systemic immunization.

Authors:  M M Dunn; D W Kamp
Journal:  Am Rev Respir Dis       Date:  1987-06

4.  A rapid, sensitive method for detection of alkaline phosphatase-conjugated anti-antibody on Western blots.

Authors:  M S Blake; K H Johnston; G J Russell-Jones; E C Gotschlich
Journal:  Anal Biochem       Date:  1984-01       Impact factor: 3.365

5.  Specificity of opsonic antibodies to enhance phagocytosis of Pseudomonas aeruginosa by human alveolar macrophages.

Authors:  H Y Reynolds; J A Kazmierowski; H H Newball
Journal:  J Clin Invest       Date:  1975-08       Impact factor: 14.808

6.  Characterization of the human immune response to a polysaccharide vaccine from Pseudomonas aeruginosa.

Authors:  G B Pier; D M Thomas
Journal:  J Infect Dis       Date:  1983-08       Impact factor: 5.226

7.  Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosa.

Authors:  H J Zweerink; M C Gammon; C F Hutchison; J J Jackson; D Lombardo; K M Miner; J M Puckett; T J Sewell; N H Sigal
Journal:  Infect Immun       Date:  1988-08       Impact factor: 3.441

8.  Characterization of a human monoclonal antibody to lipopolysaccharides of Pseudomonas aeruginosa serotype 5: a possible candidate as an immunotherapeutic agent for infections with P. aeruginosa.

Authors:  S Sawada; T Kawamura; Y Masuho; K Tomibe
Journal:  J Infect Dis       Date:  1985-11       Impact factor: 5.226

9.  Development of an enzyme-linked immunosorbent assay for studying Pseudomonas aeruginosa cell surface antigens.

Authors:  R S Borowski; L M Stock; N L Schiller
Journal:  J Clin Microbiol       Date:  1984-06       Impact factor: 5.948

10.  Protection of mice from experimental infection with type III group B Streptococcus using monoclonal antibodies.

Authors:  M L Egan; D G Pritchard; H C Dillon; B M Gray
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307

View more
  22 in total

Review 1.  Prospects for monoclonal antibodies in the diagnosis and treatment of bacterial infections.

Authors:  J Verhoef; R Torensma
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-04       Impact factor: 3.267

Review 2.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

3.  Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis.

Authors:  S Hemachandra; K Kamboj; J Copfer; G Pier; L L Green; J R Schreiber
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

4.  A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.

Authors:  Tanweer S Zaidi; Gregory P Priebe; Gerald B Pier
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

5.  Clearance of Pseudomonas aeruginosa from the murine gastrointestinal tract is effectively mediated by O-antigen-specific circulating antibodies.

Authors:  G B Pier; G Meluleni; J B Goldberg
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

6.  Functional properties of isotype-switched immunoglobulin M (IgM) and IgG monoclonal antibodies to Pseudomonas aeruginosa lipopolysaccharide.

Authors:  M Pollack; N L Koles; M J Preston; B J Brown; G B Pier
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

Review 7.  Vaccines for Pseudomonas aeruginosa: a long and winding road.

Authors:  Gregory P Priebe; Joanna B Goldberg
Journal:  Expert Rev Vaccines       Date:  2014-02-27       Impact factor: 5.217

8.  Effects of the combination of lipopolysaccharide-specific monoclonal antibodies and sparfloxacin against Pseudomonas aeruginosa pneumonia in neutropenic mice.

Authors:  K Oishi; F Sonoda; A Iwagaki; S Kobayashi; T Nagatake; K Matsumoto
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

9.  Role of neutrophils, MyD88-mediated neutrophil recruitment, and complement in antibody-mediated defense against Pseudomonas aeruginosa keratitis.

Authors:  Tanweer S Zaidi; Tauqeer Zaidi; Gerald B Pier
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-11-05       Impact factor: 4.799

10.  A protective human monoclonal antibody directed to the outer core region of Pseudomonas aeruginosa lipopolysaccharide.

Authors:  M Terashima; I Uezumi; T Tomio; M Kato; K Irie; T Okuda; S Yokota; H Noguchi
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.